News
Endogena finalises enrolment for retinitis pigmentosa trial
Endogena Therapeutics has revealed that it has completed patient enrolment for its phase 1/2a trial concerning the company’s EA-2353 candidate. The therapy has been developed to treat retinitis pigmentosa (RP).